Purified protein derivative as intralesional immunotherapy for treatment of warts: Selection of the appropriate population is crucial

J Am Acad Dermatol. 2019 Oct;81(4):e101. doi: 10.1016/j.jaad.2019.05.035. Epub 2019 May 18.

Authors

Roya S Nazarian¹, Beth N McLellan²

Affiliations

¹ Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
² Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Bronx, New York. Electronic address: bmclella@montefiore.org.

PMID: 31112726
DOI: 10.1016/j.jaad.2019.05.035

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Immunologic Factors
Immunotherapy
Network Meta-Analysis
Tuberculin
Warts*

Substances

Immunologic Factors
Tuberculin